Zobrazeno 1 - 2
of 2
pro vyhledávání: '"David Cendoya"'
Autor:
Maritta Kilpeläinen, Effrosyni D. Manali, Guus M. Asijee, C. Robalo-Cordeiro, David Cendoya, Spyridon Papiris, Jesper Rømhild Davidsen, António Morais, Stéphane Soulard, Wim A. Wuyts, Maite Artés, Jelle R. Miedema
Publikováno v:
Advances in Therapy, 37(7), 3246-3264. Springer International Publishing AG
Wuyts, W A, Papiris, S, Manali, E, Kilpeläinen, M, Davidsen, J R, Miedema, J, Robalo-Cordeiro, C, Morais, A, Artés, M, Asijee, G, Cendoya, D & Soulard, S 2020, ' The Burden of Progressive Fibrosing Interstitial Lung Disease : A DELPHI Approach ', Advances in Therapy, vol. 37, no. 7, pp. 3246-3264 . https://doi.org/10.1007/s12325-020-01384-0
Advances in Therapy
Wuyts, W A, Papiris, S, Manali, E, Kilpeläinen, M, Davidsen, J R, Miedema, J, Robalo-Cordeiro, C, Morais, A, Artés, M, Asijee, G, Cendoya, D & Soulard, S 2020, ' The Burden of Progressive Fibrosing Interstitial Lung Disease : A DELPHI Approach ', Advances in Therapy, vol. 37, no. 7, pp. 3246-3264 . https://doi.org/10.1007/s12325-020-01384-0
Advances in Therapy
Introduction The term progressive fibrosing interstitial lung disease (ILD) describes patients with fibrotic ILDs who, irrespective of the aetiology of the disease, show a progressive course of their disease despite current available (and non-license
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fecd8407729e8616e934903567eb9c1
https://hdl.handle.net/1765/127439
https://hdl.handle.net/1765/127439
Autor:
Guus M. Asijee, Spyridon Papiris, Effrosyni D. Manali, Maritta Kilpeläinen, António Morais, Jesper Rømhild Davidsen, Wim A. Wuyts, Jelle R. Miedema, Stéphane Soulard, Carlos Robalo Cordeiro, Montse Pérez, David Cendoya
Publikováno v:
Advances in Therapy, 38(1), 521-540. Springer International Publishing AG
Davidsen, J R, Miedema, J, Wuyts, W, Kilpeläinen, M, Papiris, S, Manali, E, Robalo Cordeiro, C, Morais, A, Pérez, M, Asijee, G, Cendoya, D & Soulard, S 2021, ' Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries : The BUILDup Delphi Consensus Study ', Advances in Therapy, vol. 38, no. 1, pp. 521-540 . https://doi.org/10.1007/s12325-020-01541-5
Advances in Therapy
Davidsen, J R, Miedema, J, Wuyts, W, Kilpeläinen, M, Papiris, S, Manali, E, Robalo Cordeiro, C, Morais, A, Pérez, M, Asijee, G, Cendoya, D & Soulard, S 2021, ' Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries : The BUILDup Delphi Consensus Study ', Advances in Therapy, vol. 38, no. 1, pp. 521-540 . https://doi.org/10.1007/s12325-020-01541-5
Advances in Therapy
Introduction Systemic sclerosis (SSc) is a rare chronic autoimmune disease characterised by microvascular damage, immune dysregulation and fibrosis, affecting the skin, joints and internal organs. Interstitial lung disease (ILD) is frequently associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::465218fc3922126392cc5080b304bfbc
https://pure.eur.nl/en/publications/c49f1430-b77d-4eed-8e43-c13fe1c8c05d
https://pure.eur.nl/en/publications/c49f1430-b77d-4eed-8e43-c13fe1c8c05d
